EUVIMEDEUVIMED entdecken
Open Access

Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors

Gabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, Paul Zumbo, Asim Dave, Doron Betel, Sung Wook Kang, Hee-Jin Jang, Matthew D Hellmann, Bryan M Burt, Hyun-Sung Lee, Andrea Schietinger

Cancer Cell · 2024-07 · 42 (7) · 1202-1216.e8

DOI: 10.1016/j.ccell.2024.05.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-07. Verfasst von Gabriel Espinosa-Carrasco und 11 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: gespinosa@idibell.cat. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 221-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-specific CD8+ T cells are frequently dysfunctional and unable to halt tumor growth. We investigated whether tumor-specific CD4+ T cells can be enlisted to overcome CD8+ T cell dysfunction within tumors. We find that the spatial positioning and interactions of CD8+ and CD4+ T cells, but not their numbers, dictate anti-tumor responses in the context of adoptive T cell therapy as well as immune checkpoint blockade (ICB): CD4+ T cells must engage with CD8+ T cells on the same dendritic cell during the effector phase, forming a three-cell-type cluster (triad) to license CD8+ T cell cytotoxicity and cancer cell elimination. When intratumoral triad formation is disrupted, tumors progress despite equal numbers of tumor-specific CD8+ and CD4+ T cells. In patients with pleural mesothelioma treated with ICB, triads are associated with clinical responses. Thus, CD4+ T cells and triads are required for CD8+ T cell cytotoxicity during the effector phase and tumor elimination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesCD4-Positive T-LymphocytesHumansAnimalsMiceImmunotherapyNeoplasmsImmune Checkpoint InhibitorsMice, Inbred C57BLImmunotherapy, AdoptiveDendritic CellsCell Line, TumorTumor Microenvironment

Stichwörter der Autor:innen

CD4 T cellCD8 T cellCanceradoptive T cell transfercancer immunotherapydendritic cellimmune checkpoint blockadetriadtumortumor antigen

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: gespinosa@idibell.cat.
  • Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Developmental and Molecular Biology, and Institute for Aging Studies, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA; Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.
  • Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA; Division of Hematology and Medical Oncology, Department of Medi…
  • Systems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • NCRR NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • National Institutes of Health
  • National Cancer Institute
  • AstraZeneca
  • American Association for Cancer Research

Zitieren

APA

Espinosa-Carrasco, G., Chiu, E., Scrivo, A., Zumbo, P., Dave, A., Betel, D., Kang, S. W., Jang, H. J., Hellmann, M. D., Burt, B. M., Lee, H. S., & Schietinger, A. (2024). Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell, 42(7), 1202-1216.e8. https://doi.org/10.1016/j.ccell.2024.05.025

Vancouver

Espinosa-Carrasco G, Chiu E, Scrivo A, Zumbo P, Dave A, Betel D, et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell. 2024;42(7):1202-1216.e8. doi:10.1016/j.ccell.2024.05.025

BibTeX
@article{EspinosaCarrasco2024,
  author = {Espinosa-Carrasco, Gabriel and Chiu, Edison and Scrivo, Aurora and Zumbo, Paul and Dave, Asim and Betel, Doron and Kang, Sung Wook and Jang, Hee-Jin and Hellmann, Matthew D and Burt, Bryan M and Lee, Hyun-Sung and Schietinger, Andrea},
  title = {Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {7},
  pages = {1202--1216.e8},
  doi = {10.1016/j.ccell.2024.05.025}
}
Kostenlos starten →